|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 503 active entries
313 Pleasant St
United States of America, Massachusetts
Preclinical ADME Tox Contract Research
Cyprotex (www.cyprotex.com) was founded in 1999 and specialises in in vitro and in silico ADME-Tox. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during preclinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and modelling and simulation expertise. The company has sites at Alderley Park near Manchester in the UK and in Watertown near Boston in the US. In 2016, Cyprotex was acquired by Evotec AG (www.evotec.com). As a whole, the Group offer integrated and stand-alone drug discovery capabilities as well as full CMC and IND-enabling services, allowing the company to provide expert support across the value chain from early discovery through to preclinical development and beyond.
Last update of this entry: September 29, 2020